» Articles » PMID: 11061852

Evaluation of the Effectiveness of Targeted Lookback for HCV Infection in the United States-interim Results

Overview
Journal Transfusion
Specialty Hematology
Date 2000 Nov 3
PMID 11061852
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: As part of a nationwide program to identify persons at increased risk for HCV infection, persons who received blood from donors who later tested positive for anti-HCV are being directly notified.

Study Design And Methods: In December 1999, all 198 blood collection establishments (BCEs) and 5442 hospital transfusion services (TSs) in the United States were surveyed by mailed questionnaire to evaluate their progress in carrying out this notification.

Results: Eighty-one percent of the BCEs and 64 percent of the TSs responded. After correcting for nonresponse, an estimated 98,484 components at potential risk for transmitting HCV, according to previous testing of multiantigen-screened donors, were identified nationwide, of which 85 percent had been transfused to recipients. Lookback for these recipients was completed for 80 percent, of whom 69 percent had died. Of those living, 78 percent were successfully notified. An estimated 49.5 percent of those notified were tested; 18.9 percent of those tested were anti-HCV positive, and 32 percent of that group knew they were positive before notification. On the basis of an 85.5 percent reported completion rate for component notifications back through 1988, an estimated 1520 persons will have been newly identified as anti-HCV-positive when lookback related to multiantigen screening of donors is completed.

Conclusion: Targeted lookback related to previous multiantigen screening of donors will identify <1 percent of the estimated 300,000 HCV-positive persons in the United States who may have acquired their infection via blood transfusion.

Citing Articles

Transmission of viral hepatitis through blood transfusion in Sweden, 1968 to 2012.

Dahl V, Majeed A, Wikman A, Norda R, Edgren G Euro Surveill. 2020; 25(29).

PMID: 32720634 PMC: 7384284. DOI: 10.2807/1560-7917.ES.2020.25.29.1900537.


Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016.

Nolen L, Gustin C, Seeman S, Murphy N, Truitt S, Schillie S Can J Gastroenterol Hepatol. 2019; 2019:8654741.

PMID: 31275902 PMC: 6582887. DOI: 10.1155/2019/8654741.


The Spatial Distribution of Hepatitis C Virus Infections and Associated Determinants--An Application of a Geographically Weighted Poisson Regression for Evidence-Based Screening Interventions in Hotspots.

Kauhl B, Heil J, Hoebe C, Schweikart J, Krafft T, Dukers-Muijrers N PLoS One. 2015; 10(9):e0135656.

PMID: 26352611 PMC: 4564162. DOI: 10.1371/journal.pone.0135656.


The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

Rein D, Wittenborn J, Smith B, Liffmann D, Ward J Clin Infect Dis. 2015; 61(2):157-68.

PMID: 25778747 PMC: 5759765. DOI: 10.1093/cid/civ220.


Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis.

Hare C, Loveland J, Chu A, Morris J, Gotz V, Klaskala W Curr Ther Res Clin Exp. 2014; 66(5):433-50.

PMID: 24790244 PMC: 4003805. DOI: 10.1016/j.curtheres.2005.10.005.